Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Read it. And agree there is a lack of transparency, but that is not what is hurting the stock. Slow sales increase is hurting the stock,
I will be watching weekly sales. A minimum of 300 to 400 weekly increases in prescriptions will increase the stock price.
Without that increase in prescriptions we longs lose and the shorts win.
Congratulations on your investment, if you still own it.
I will stick with SGYP now. I have found success buying when others are selling and selling when others are buying.
I am concerned that we are overdue for a substantial pullback on biotec stocks after the year long rise we have just had.
took informiner777 post to heart. Added another 5000 shares at $2.02 this morning.
He was referring to me as a short. I am not, just another trapped long that thought his post lacked an analytical approach, but instead tried to validate his post by using his resume.
As to your post, hopefully your assessment is near correct. Not being privy to their use of funds, please consider
1)They may have used a portion of the $100 million dollar draw to repay the short-term loan that allowed them to reach their cash requirement.
2) Since they are ramping up rep and marketing costs their cash burn most likely is increasing proportionately.
So about the best we can say is that they have cash available to last between 3 and 5 quarters.
Wouldn't we all feel much better if the officers and directors purchased SUBSTANTIAL shares in the open market.
With your background I am surprised that you do not understand. They borrowed money from another lender to get the cash balance up, so they could borrow even more money from the existing lender.
The net result is they are spending more and more borrowed money with no current way to pay it back.
The executives are gambling they will be able to turn the company around before the lenders take control of their only asset and leave stockholders with nothing.
It is not much of a gamble for the executive team since they have very, very little skin in the game.
Of course there is a possibility that a deal was structured a while ago that allowed hedge funds to short the stock because they had already agreed to be buyers of an additional offering of 40-50 million shares shares on 1/31 based on a discount to today or tomorrows closing price.
If so, we will know that management is ethically challenged and put their personal greed ahead of solid business practices.
The uncertainty factor regarding the financing is now equalized and might slightly favor the longs. Would anticipate some short covering in the last 2 hours today.
We will see what we see.
There has been so much dilution and more to come that even getting back to $3 per share could take a long time. The company is not profitable so no metric there and even on a price to sales basis, every time the company dilutes the share count the price to sales ratio goes down.
This company needs to be sold or merged now, IMO
Old news. We knew this 2 days ago and the price has dropped over 10% since then. A lot of commentary on this from many sources. Until this company straightens out its finances and quits screwing existing shareholders (like it continually has) the stock price is going nowhere.
No statement today from troy Hamilton. Unless you mean that the lack of a statement in the continual downdraft is the statement
Thanks Dew
Volume!!
only the 4th 500,000+ volume day in the last 12 months.
Indeed it is!!!!
Indeed it is!!!!
SGMO - What you may be missing about SGMO (posted on another board by ericseb1)
Deals and data.
1) Car-T deal can come anytime. After one-on-one meetings w/ two distinct analysts this summer, both independently reported they were given indication Car-T deal by year-end was expected. This may have subsequently slipped a month or two, but good odds given their best in class tech and BP appetite to lock up I/O assets that we lock down terms early '18 at latest.
2) Hemo-A data. We're going to dose our 3rd patient shortly. JPM HC conference (starts Jan 8, 2018) is an ideal forum to announce prelim safety/efficacy data for this trio of gene therapy patients.
3) MPS data. Now that dosing has been initiated and a 'pipeline' of followers is readied to follow, Cowen has suggested World Symposium (lysosomal disease forum) starting Feb 5th could be perfect timing for us to have early safety/efficacy data.
4) NHP Tau data. Non-human primate data should be ready very early 2018 for our TAU program, and news on this front which will be fodder for most lucrative deal will be major catalyst for stock and it's prospects. Last hurdle needed before $$$ deal.
With all four of these catalysts likely in next 3 months, and EVERY DAY that passes w/o adverse event news on Hemo A and MPS meaning safety is a non-issue, think the trend will most definitely be UP almost each and every week barring major market meltdown.
Let's not forget, #3, MPS data, is PLATFORM VALIDATING. If it works for this IVPRP target, it should work for all. Feb news is TRANSFORMATIONAL if biomarkers show it is working, and working safely.
So not sure when those who sold might expect a pullback, as their is A VERY SHORT WINDOW BEFORE VERY HUGE CATALYSTS!!!
I added yesterday, and many other occasions during the pull back this week. We may see a 13 price print before the decline stops, but we could see 18 or higher on any news. It is not worth the risk of missing out on a large price increase just to buy a point lower.
followed by a 4.5% increase in price on even less volume.
Getting close to ATM selling? If so, may be a significant drop in price as price increase has been on limited upside volume.
Micro spike in volume caused a 3.5% price increase today 9/25.
MTSL (BioInvest) Issue 860: SGMO - company update
SGMO – Presents Preclinical Oncology Platform; Partnership Soon
SGMO presented preclinical data demonstrating the Company’s engineering capabilities in T cell genome editing using zinc finger nucleases (ZFNs) at the Immuno-Oncology Summit in Boston (8/28-9/1 http://www.immuno-oncologysummit.com). The talk, entitled “Engineering T Cells for Cancer Therapeutics,” showed off Sangamo’s cell therapy expertise and included data from the Company’s recent research in the development of allogeneic T cell immunotherapies utilizing ZFN editing techniques. Highlights of the platform include:
1. Elimination of endogenous T cell receptor (TCR) expression by knock-out of the TCR alpha constant locus (TRAC) with greater than 90% efficiency
2. Elimination of human leukocyte antigen (HLA) Class I proteins by knock-out of b2-microglobulin (B2M) with greater than 90% efficiency
3. Co-delivery double knock-out of TRAC and B2M with greater than 90% efficiency
4. Targeted integration of a green fluorescent protein (GFP) expression cassette into either the TRAC or B2M locus with ~90% efficiency with double knock-out of TCR and HLA Class I
5. CD19 chimeric antigen receptor (CAR) integrated into either the TRAC or B2M locus demonstrated strong antigen specific killing with a clear dose response
6. No evidence of off-target cleavage in human primary T cells
Through the company’s original T cell genome editing programs, Sangamo has accumulated clinical expertise in therapeutic T cell development and manufacturing of clinical grade materials. In approximately 100 HIV patients treated with ZFN-edited T cells, SGMO has demonstrated persistent engraftment and established a strong safety profile for the duration of observation (3 years post infusion). SGMO’s technology has the potential to create off the shelf CAR-Ts and significantly improve the manufacturing process which would create a much larger market opportunity.
Gene editing remains one of the more exciting drug development technologies today. The Company is ideally suited for allogeneic or autologous approaches with its ex-vivo clinical and manufacturing experience in cell engineering and development. Dr. Lee’s slides are here (http://c.eqcdn.com/sangamo/files/documents/GLee_IO+Summit+Aug2017+vFINAL.pdf).
We believe SGMO is well-positioned yet unrecognized by most investors in immuno-oncology. A corporate collaboration with an experienced cancer company is possible by the end of 2017. The Company is already engaged with potential partners and a deal would not only bring favorable economic terms but more importantly, validate SGMO as a participant in the I/O world. In our view, SGMO’s experience in T-cells and its proprietary ZFN technology uniquely position the company to be a leader in developing the next generation CAR-Ts.
New Seeking Alpha article on Sangamo (SGMO)
https://seekingalpha.com/article/4099708-sangamo-therapeutics-breakthrough-gene-therapy
Major position
SGMO
Substantial position
NBIX
RVNC
Small Positions
ENTA
OMER
BEAT
Amusement
XXII
BLCM
Sangamo (SGMO) Another 52 week high today. Now $11.15 around $3.00 at the start of the year.
If you have questions about SGMO the SGMO board at Investor Village has many scientifically knowledgeable posters
Sangamo (SGMO)
Quarterly conference calls accompanying slide presentation
http://c.eqcdn.com/_80c3e099cb1a1e98657d405ef95649a3/sangamo/db/233/1396/presentation/SGMO+Q2+2017+Deck+vFINAL-1.pdf
Is a year enough to prove themselves?
No.
Gives them a year to prove they are worth further investment next year.
Might need the $75 mil because they burn $15 million per quarter. As of June 30th they had enough cash and investments to fund 1 year of operations. They have no apparent sources of new cash so the offering gives them another year to prove they are worth further investment.
SGMO - Sangamo hits new 52 week high in trading today.
Sangamo Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on translating ground-breaking science into genomic therapies that transform patients' lives using platform technologies in genome editing, gene therapy, gene regulation, and cell therapy. The company?s proprietary zinc finger DNA-binding protein (ZFP) technology enables specific genome editing and gene regulation. The ZFPs could be engineered to make ZFP nucleases (ZFNs), proteins that could be used to specifically modify DNA sequences by adding or knocking out specific genes; and ZFP transcription factors (ZFP TFs), proteins that can be used to turn genes on or off. Its therapeutic products include SB-728-T, a ZFN-mediated autologous T-cell product for human immunodeficiency virus and acquired immunodeficiency syndrome (HIV/AIDS), which is in Phase II and Phase I clinical trials; and SB-728-HSPC that is in Phase I/II clinical trials for HIV/AIDS. The company also engages in Phase I/II studies of in vivo genome editing applications of ZFP Therapeutics for hemophilia B, Hemophilia A, and Mucopolysaccharidosis I (MPS) and MPS II, which are lysosomal storage disorder (LSD); proprietary preclinical programs in other LSDs; and research stage programs in certain central nervous system disorders and cancer immunotherapies. It has collaborative partnerships with Biogen Inc. to develop therapeutic genome editing products in hemoglobinopathies; and with Shire International GmbH to develop the preclinical development program in Huntington?s disease, as well as license agreement with Sigma-Aldrich Corporation to develop ZFP-based laboratory research reagents and Dow AgroSciences, LLC to modify the genomes or alter protein expression of plant cells, plants, or plant cell cultures. The company was formerly known as Sangamo BioSciences, Inc. and changed its name to Sangamo Therapeutics, Inc. in January 2017. Sangamo Therapeutics, Inc. was founded in 1995 and is headquartered in Richmond, California.
Initial investment today. Still have a low ball buy outstanding.
SGMO - Sangamo Receives Fast Track Designation From The FDA For SB-318 And SB-913 In Vivo Genome Editing Product Candidates For The Treatment Of MPS I And MPS II
https://finance.yahoo.com/news/sangamo-receives-fast-track-designation-200100677.html
Anyone else think that the current manufacturing situation means that this company will be sold sometime within the next few months. Should be painfully obvious to the large institutional holders of OCUL that the pipeline is much more valuable in someone else's hands. Therefore, worth much more to the current shareholders then reflected by the current price.
Price drop due to a $150 million shelf offering filed with the SEC. Lot of potential dilution.
Sangamo Therapeutics (SGMO) Appoints Roger Jeffs, Ph.D. and Joseph S. Zakrzewski to its Board of Directors
Dr. Jeffs currently serves as a Senior Advisor to United Therapeutics Corp., where he worked for 18 years, most recently as President and co-CEO. He has over 25 years of experience in the biopharmaceutical industry in R&D, clinical development, regulatory and medical affairs. While at United Therapeutics, Dr. Jeffs led the clinical development, regulatory approval and commercialization of six rare disease products. Prior to joining United Therapeutics, he held positions in clinical development at Amgen, Inc. and Burroughs Wellcome Co. Dr. Jeffs currently serves as a member of the board of directors of Axsome Therapeutics and Dova Pharmaceuticals. He received a B.A. in Chemistry from Duke University and his Ph.D. in Pharmacology from the University of North Carolina.
Mr. Zakrzewski has over 25 years of experience in the biopharmaceutical industry with senior leadership experience in R&D, supply chain and manufacturing operations, business development and commercialization. From 2010 through 2013, he was Chairman and CEO of Amarin Pharmaceuticals, where he led the development and commercialization of the company's first product, Vascepa. Mr. Zakrzewski previously served as a Venture Partner with Orbimed Advisors, a venture capital firm, and as Chairman, President and CEO of Xcellerex, a privately held company focused on the commercialization of its proprietary manufacturing technology for biotherapeutics and vaccines. Earlier, he served as COO of Reliant Pharmaceuticals before its acquisition by GlaxoSmithKline in 2007 and held various executive positions at Eli Lilly & Company in the areas of R&D, manufacturing, finance and business development. Mr. Zakrzewski currently serves as a member of the board of directors of various public and private companies, including Acceleron Pharma, Amarin Pharmaceuticals Insulet Corporation and Onxeo SA where he serves as Chairman. Mr. Zakrzewski received a B.S. in Chemical Engineering and an M.S. in Biochemical Engineering from Drexel University, and an MBA in Finance from Indiana University
something else in my opinion. Now at $9.30. $2.05 (about 25%) over yesterdays small capital raise
And today Sangamo (SGMO) establishes a new 52 week high of $8.70
Notes by a poster that attended Sangamo (SGMO) annual meeting.
https://www.investorvillage.com/smbd.asp?mb=1933&mn=87933&pt=msg&mid=17270380
you pay 55 cents for the right to purchase a share at $4.25 or lower dependent on the closing price on Tuesday. The right is not tradable.
I believe it is by Tuesday next week.
Entered my subscription and over subscribed by the same amount. This will triple my holdings of EYES.
read:
APRI may have slightly more cash than debt at this current time, but barely.
should have read:
APRI does not have sufficient cash to pay the debt, if called.
APRI may have slightly more cash than debt at this current time, but barely. Further management is not predicting to be cash flow positive this year. In which case the company will have more debt than cash by the end of the year.
They may very well be in default of the 10 million credit facility right now. If in default and the loan were called, APRI would have to use nearly all its cash to pay off the debt. The credit facility is secured by all of the tangible and intangible assets of APRI. That includes Vitaros and all future revenues of Vitaros. Whoever owns the debt technically owns Vitaros.
The question then, is it better for a major investor to invest in APRI and own a part of the pie, or buy the debt and own 100% of Vitaros.
If someone makes a major investment in APRI now, they also inherit all the other stockholders, the credit facility, the lease, the outstanding warrants and options, and any other past commitments.
Why would that be appealing?
Well from the top of my head. Vitaros, then the RTD device, then Rayva, then it was Femprox, back to the RTD device, then it was back to Rayva, then it was Fispemifene, then back to Vitaros.
Oh, then there was the expansion of territories for Vitaros, and Canadian approval. There are probably more.
Heck, that's just the last 3 years.
This group has not executed. Why?
Either they have nothing of value to develop, or they are just incompetent.